These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30881571)

  • 1. Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.
    Del Rosso JQ; Kircik L; Lin T; Pillai R
    J Clin Aesthet Dermatol; 2019 Jan; 12(1):11-15. PubMed ID: 30881571
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
    Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
    J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
    Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
    J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
    Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.
    Bhatia ND; Pariser DM; Kircik L; Lin T; Harris S; Mathew L; Pillai R
    J Clin Aesthet Dermatol; 2018 Nov; 11(11):15-19. PubMed ID: 30588269
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
    Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
    J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 12. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
    Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
    J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
    Ramachandran V; Bertus B; Bashyam AM; Feldman SR
    Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
    Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
    J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
    Tanghetti EA; Bhatia N; Drew S; Jacobson A
    J Drugs Dermatol; 2021 Aug; 20(8):829-836. PubMed ID: 34397206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
    Tyring S; Kircik LH; Yamauchi P; Jacobson A; Lin T
    J Drugs Dermatol; 2020 Apr; 19(4):389-396. PubMed ID: 32272516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis.
    Kircik L; Jacobson A
    J Drugs Dermatol; 2024 Feb; 23(2):50-53. PubMed ID: 38306148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis.
    Adam DN; Jablonski Bernasconi MY; Thoning H; Wu JJ
    Dermatol Ther (Heidelb); 2022 Nov; 12(11):2589-2600. PubMed ID: 36223060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.
    Lebwohl MG; Stein Gold L; Papp K; Han G; Pariser DM; Lin T; Harris S; Jacobson A
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):1152-1160. PubMed ID: 33428282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.